Nuvation Bio beats Q3 revenue expectations, driven by IBTROZI sales

Nuvation Bio

03/11/2025 21:22

Overview

Nuvation Bio beat analysts' expectations for Q3 revenue, driven by IBTROZI sales

Company reported Q3 net loss of $55.8 mln

204 patients started on IBTROZI in Q3, indicating strong launch progress

Outlook

Company expects $25 mln milestone payment from Nippon Kayaku by year-end

Nuvation Bio plans sNDA to update IBTROZI label with recent data

Company expects taletrectinib listing on China's National Reimbursement Drug List in 2026

Result Drivers

IBTROZI LAUNCH - 204 patients started treatment with IBTROZI in Q3, reflecting strong launch progress

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$13.12 mln
$6.61 mln (7 Analysts)
Q3 EPS
-$0.16
Q3 Net Income
-$55.79 mln
Q3 Income from Pperations
-$56.43 mln
Q3 Operating Expenses
$66.20 mln
Q3 Pretax Profit
-$55.79 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Nuvation Bio Inc is $10.00, about 47.8% above its October 31 closing price of $5.22

Press Release: ID:nBw3hfs1Za

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)